Enanta Pharmaceuticals | ENTA - Nettoeinkommen





Nettoeinkommen Veränderung Datum
AbbVie USD 695M 1.12B 2026-03
Amgen USD 1.82B 486M 2026-03
Anika Therapeutics USD 292K 2.62M 2025-12
Arrowhead Research USD 30.81M 54.56M 2025-12
AstraZeneca USD 3.08B 754M 2026-03
BioCryst Pharmaceuticals USD 245.84M 232.95M 2025-12
Biogen USD 319.5M 368.4M 2026-03
Bristol-Myers Squibb USD 2.68B 1.59B 2026-03
Enanta Pharmaceuticals USD -22.29M 93.76M 2024-12
Gilead Sciences USD 2.18B 869M 2025-12
GlaxoSmithKline GBP 1.74B 1.1B 2026-03
Halozyme Therapeutics USD -141.59M 316.82M 2025-12
Heron Therapeutics USD -2.95M 14.54M 2025-12
Immunic USD -19.3M 6.28M 2025-12
Incyte USD 303.33M 4.05M 2026-03
Insmed USD -328.48M 41.54M 2025-12
Ionis Pharmaceuticals USD -93M 136M 2026-03
J&J USD 5.24B 119M 2026-03
Karyopharm Therapeutics USD -102.2M 71.42M 2025-12
Ligand Pharmaceuticals USD 117.27M 112.43M 2025-09
Merck USD -4.24B 7.2B 2026-03
Neurocrine Biosciences USD 153.7M 55.8M 2025-12
Novartis USD 3.16B 747M 2026-03
Novavax USD 17.53M 219.91M 2025-12
Pfizer USD -1.65B 5.19B 2025-12
PTC Therapeutics USD -134.96M 150.86M 2025-12
Roche Holding CHF 5.47B 1.76B 2025-12
Sarepta Therapeutics USD -412.23M 232.28M 2025-12
Vertex Pharmaceuticals USD 1.03B 159.7M 2026-03